Fuhrman Alan 4

What Happened

• Alan Fuhrman, Chief Financial Officer of Tyra Biosciences (TYRA), received equity awards on May 5, 2026: 20,000 shares plus 67,000 derivative awards (total 87,000 units) at $0.00 per unit (grant/award, not a purchase or sale). The filing reports $0 cash consideration for these awards. These awards represent compensation rather than open-market buying or selling.

Key Details

• Transaction date: May 5, 2026; Form 4 filed May 7, 2026 (timely, within the usual two-business-day window).
• Grants: 20,000 shares @ $0.00 (awarded); 67,000 derivative units @ $0.00 (awarded) — combined total = 87,000 units.
• Shares owned after transaction: Not specified in the filing.
• Footnotes of note:
  • F1: The grants are restricted stock units (RSUs). 1/4 of the total RSUs vests on each of the first four anniversaries of May 5, 2026, subject to continuous service. Each vested RSU converts to one share.
  • F2: Confirms that the derivative amount includes RSUs.
  • F3: Separately notes a typical option vesting cadence of 1/48th monthly after May 5, 2026 (applies to option grants, if any, and is subject to service).
• Transaction code: A = Award/Grant.

Context

• This was an equity grant as part of compensation; such awards are routine for executives and do not reflect an immediate market purchase or sale. The RSUs vest over time (quarterly annual cliffs per F1), so shares will only be delivered if Fuhrman remains in service and conditions are met. The filing does not indicate any immediate sale or cashless exercise connected to these awards.